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Background: Chikungunya is a highly debilitating febrile illness caused by Chikungunya virus, a single-stranded
RNA virus, which is transmitted by Aedes aegypti or Aedes albopictus mosquito species. The pathogenesis and host
responses in individuals infected with the chikungunya virus are not well understood at the molecular level. We
carried out proteomic profiling of serum samples from chikungunya patients in order to identify molecules
associated with the host response to infection by this virus.
Results: Proteomic profiling of serum obtained from the infected individuals resulted in identification of 569
proteins. Of these, 63 proteins were found to be differentially expressed (≥ 2-fold) in patient as compared to control
sera. These differentially expressed proteins were involved in various processes such as lipid metabolism, immune
response, transport, signal transduction and apoptosis.
Conclusions: This is the first report providing a global proteomic profile of serum samples from individuals infected
with the chikungunya virus. Our data provide an insight into the proteins that are involved as host response factors
during an infection. These proteins include clusterin, apolipoproteins and S100A family of proteins.
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Chikungunya is an endemic disease in Africa and South-
East Asia. Some isolated cases have also been reported
in parts of Europe, Australia and America in the past
decade [1-3]. Although the infection was considered to
be arthritogenic, cases of meningoencephalitis and sub-
sequent mortality have also been documented [4-6]. The
persistent and painful arthralgia observed in this disease
significantly reduces the ability to work among the
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distribution, and reproduction in any mediumChikungunya virus (CHIKV) is an arbovirus belonging
to the family Togaviridae and genus Alphavirus. Its gen-
ome consists of 12 kb single-stranded RNA, which codes
for 4 non-structural and 5 structural proteins. A muta-
tion in the viral genome leading to a single amino acid
change of alanine to valine at the position 226 (A226V) of
the E1 glycoprotein [7], enhances its survival and trans-
mission through the widely distributed vector- Aedes
albopictus [8,9]. This has also been shown to enhance
the dissemination of the virus into temperate regions,
in addition to its tropical hot-spots in the native regions of
Africa and South-East Asia [10-12].
Following the bite of an infected mosquito, the virus
replicates in the skin before being disseminated to other
parts of the body including liver, spleen, muscle, joints
and occasionally choroid plexus of the central nervous
system [4,13,14]. Clinically, the disease presents with an
acute onstage of fever, rigors, headache and occasional
rashes followed by severe joint pain lasting weeks toentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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during the acute stage [17]. Confirmatory diagnosis of chi-
kungunya involves the use of RT-PCR based detection of
chikungunya viral transcript and/or IgG or IgM capture
ELISA [18,19]. Initial screening through monitoring of
interleukin levels and subsequent confirmation of viral
glycoproteins by ELISA cannot be easily implemented in
remote rural areas.
Various research groups have investigated the pathogen-
icity and the mechanism of CHIKV infection [14,20,21].
Symptoms associated with chikungunya have been pro-
posed to be of an immunopathogenic origin caused due to
cytokines. Levels of cytokines have been studied to under-
stand the clinical manifestations observed in patients.
Among them, cytokines such as IL-1 and IL-6 have been
shown to be elevated in the acute stage, with persistently
higher levels of IL-6 in patients with continued arthralgia
[22-25]. The cytokine levels in chikungunya patients have
also been associated with the severity of infection [22].
Cytokine profiles have been shown to vary with the viral
loads and the stages of infection [23]. Recent advances
in the development of macaque models and arthritic
mouse models for chikungunya may provide an opportun-
ity for further understanding of the disease at a molecular
level [26,27]. A recent analysis of the genetic predispos-
ition of individuals from affected families suggests that
people with O + ve blood group are more susceptible to
chikungunya infection. This study also found that Rh
negative individuals were more resistant to chikungunya
infection [28]. Although studies focusing on a limited
panel of cytokines have been studied in the context of chi-
kungunya, a more comprehensive study to investigate the
entire serum proteome profile has not yet been reported.
Thus, we performed a global quantitative proteomic

























Figure 1 Protein distribution. Proteins identified are plotted against the
when compared to that of controls. Red colored dots represent the differealong with unaffected controls using high-resolution mass
spectrometry.
Results and discussion
We carried out an iTRAQ-based quantitative proteomic
profiling of serum samples from chikungunya patients
and control individuals after immunoaffinity-based de-
pletion of abundant serum proteins, in vitro labeling
with iTRAQ reagents and SCX fractionation followed by
high resolution Fourier transform mass spectrometry
(LTQ-Orbitrap Velos). From this, we acquired a total of
112,419 tandem mass spectra, which were searched
using two search algorithms - SEQUEST and Mascot -
against a total of 33,987 proteins as provided in the Hu-
man RefSeq database version 52. We obtained 27,809
peptide-spectrum matches (PSMs) corresponding to 3,803
peptides and 569 proteins. Of these 569 proteins, identifi-
cation of 367 proteins was supported by 2 or more pep-
tides, while 202 protein identifications were based on
single peptide evidence. A comparison of the proteomic
data obtained from this study with the proteins annotated
in the Plasma Proteome Database [29] confirmed that 522
of 569 proteins identified in this study have been previously
reported from the serum or plasma [29]. We submitted the
results of this analysis to public repositories including
PRIDE (http://www.ebi.ac.uk/pride) [30] and Human
Proteinpedia (http://www.humanproteinpedia.org) [31].
We found 63 proteins to be differentially expressed
(≥ 2-fold) (Figure 1) between the serum samples from
patients and controls. Of these, 28 differentially expressed
proteins were identified by multiple peptides and 17 protein
identifications were based on single peptide evidence with
multiple PSMs. Thirty five of these proteins were more
abundant in chikungunya patient sera when compared to
that from controls, while the remaining 28 proteins were300 400 500 600
roteins
logarithmic values of their fold change in chikungunya serum samples
ntially expressed proteins (≥ 2-fold).
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trieved information on molecular functions and bio-
logical processes for the identified proteins from
Human Protein Reference Database (HPRD) (http://www.
hprd.org) [32,33]. The differentially expressed proteins
identified in this study were found to be involved in
biological processes such as protein metabolism, im-
mune response, cell communication and transport and
included molecules with catalytic and transporter ac-
tivities (Figure 3A and 3B). We also subjected these
differentially expressed proteins into a network ana-
lysis using GeneSpring software (version 12.5), which
revealed an interaction network of 17 differentially
expressed proteins, including apolipoproteins and S100A
family proteins (Figure 3C). Functional analysis of these dif-
ferentially expressed proteins revealed the overexpression
of RNA binding proteins such as ATP-dependent RNA
helicase (DDX23), sterile alpha motif domain-containing
protein 3 (SAMD3); and extracellular matrix structural






SH3 and PX domain-containing
protein 2B
DLST NP_001017995.1
2 Optineurin OPTN NP_001008214.1





5 Apolipoprotein A-IV APOA4 NP_000473.2





8 Haptoglobin isoform 1 preproprotein HP NP_005134.1
9 Glutamyl aminopeptidase ENPEP NP_001968.3
10 Clusterin CLU NP_001822.3protein (COMP) and chitinase-3-like protein 1 (CHI3L1).
In contrast, DNA binding proteins such as histones
(HIST2H3C and HIST1H4I) and tet methylcytosine
dioxygenase 1 (TET1), along with macrophage recep-
tor (MARCO) and low affinity immunoglobulin gamma
Fc region receptor III-B (FCGR3B); and serine-type
peptidases such as elastase, neutrophil expressed (ELANE),
myeloblastin precursor (PRTN3) and cathepsin preprotein
(CTSG) were found to be downregulated.
Serum is a challenging body fluid for mass spectrometry-
based proteomic investigations. To our knowledge, there is
no published report of an unbiased global investigation of
serum proteome in the context of chikungunya fever apart
from limited targeted quantitative studies to measure the
circulating levels of certain cytokines, chemokines and
growth factors (e.g. IL-6, IL-8, IL-beta) [22-25]. Our study
presents the first account of the changes in serum protein
levels in chikungunya infected individuals. Using 2D gel
electrophoresis and mass spectrometry, 6 proteins includ-
ing apolipoprotein A-IV (APOA4) and serotransferrin (TF)es of chikungunya patients
Description Fold change
(chikungunya/control)
It is an adapter protein and is involved in
cell adhesion and migration of numerous
cell types. It interacts with Fas-ligand, which
is a cytotoxic effector molecule of T and
NK cells.
6
It is a coiled-coil containing protein that
interacts with viral protein and may utilize
tumor necrosis factor-alpha or Fas-ligand
pathways to mediate apoptosis, inflammation
or vasoconstriction.
5




It is a mitochondrial matrix enzyme that
hydrolyzes ATP to convert succinate to
succinyl-CoA.
4
Apolipoproteinis an activator of lecithin-cholesterol
acyltransferase.
4
It is known to be activated upon
differentiation of monocytes to
macrophages.
4
It is a component of the U5 snRNP complex
and has been reported to be upregulated
upon induction of viral replication.
3
Haptoglobin binds to free plasma hemoglobin,
and enables hemoglobin degradation. It also
prevents loss of iron through kidneys and protects
damage of kidneys from hemoglobin.
3
It is an aminopeptidase and is involved in the
regulation of blood pressure.
2
It is a secreted chaperone. It is known to be
involved in events such as cell death and
neurodegenerative disorders.
2
Table 2 Partial list of proteins downregulated in serum samples of chikungunya infected patients
Protein Gene symbol RefSeq accession Description Fold change (control/
chikungunya)
1 Azurocidin preproprotein AZU1 NP_001691.1
It is an azurophil granule antibiotic protein, with
monocyte chemotactic and antibacterial activity.
2
2 Peroxiredoxin-2 isoform a PRDX2 NP_005800.3
It plays an antioxidant protective role in cells, and
it may contribute to the antiviral activity of
CD8 (+) T-cells.
2
3 Annexin A1 ANXA1 NP_000691.1
It is a calcium-dependent phospholipid binding
proteins with potential anti-inflammatory activity.
3
4 Lipocalin-1 isoform 1 LCN1 NP_002288.1
Lipocalins are extracellular transport proteins that
bind to a variety of hydrophobic ligands. Lipocalins
are overproduced in response to multiple stimuli
including infection and stress.
4
5 Protein S100-A9 S100A9 NP_002956.1
It is a calcium-binding protein and a member of
the S100 family, involved in the regulation of cell






It is a serine protease, which hydrolyzes proteins
within azurophil granules and that of extracellular
matrix following the protein’s release from
activated neutrophils. The enzyme may play a
role in degenerative and inflammatory diseases.
5
7 Myeloblastin PRTN3 NP_002768.3
It is a serine protease found in the azurophilic
granules in neutrophil granulocytes.
6
8 Cathepsin G preproprotein CTSG NP_001902.1
It is a member of the peptidase S1 protein family
and is found in azurophil granules of neutrophilic
polymorphonuclear leukocytes. It may participate
in the killing and digestion of engulfed pathogens,
and in connective tissue remodeling at sites of
inflammation.
6
9 Protein S100-A7 S100A7 NP_002954.2
It is a member of S100 family of proteins but lacks
calcium binding ability. It is markedly over-expressed
in the skin lesions of psoriatic patients, but is







Sac1 is a phosphoinositide lipid phosphatase that
removes the phosphate residue from the inositol
head group of PI(4)P.
16
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brain and liver of mice infected with chikungunya virus
[20]. We also observed the overexpression of APOA4 in
serum of chikungunya infected patients. Although we iden-
tified serotransferrin from serum, we did not find it to be
differentially expressed. Of the three proteins reported to
be downregulated in the mouse study, expression of cata-
lase was in agreement with our study.
Proteins such as apolipoprotein A1 (APOA1), hapto-
globin related protein (HPR) and clusterin (CLU) were
found to be overexpressed in chikungunya serum samples.
These three proteins were also reported to be overexpressed
in serum samples of dengue infected individuals when
compared to that of controls (Figure 4) [34,35]. How-
ever, clusterin has previously been reported to be
downregulated in serum of malaria patients (Figure 4)
[36,37]. Apolipoprotein C1 (APOC1) and APOA4 were
found to be overexpressed in our study while they have
been reported to be downregulated in serum of dengueinfected individuals (Figure 4) [34,35]. APOA4 has previ-
ously been shown to be downregulated in malaria patients
(Figure 4) [36,37].
We observed the downregulation of proteins that are
known to be involved in the chemotaxis of neutrophils
and phagocytes as a part of immune response to infection,
including azurocidin (AZU1), annexin A1 (ANXA1), CTSG,
S-100 calcium binding proteins S100A7, S100A8, S100A9
and transforming growth factor, beta 2 (TGFB2) from chi-
kungunya serum samples. Proteins involved in clathrin me-
diated endocytosis such as APOC1, APOA4, APOA1,
APOA2 and clusterin were abundantly expressed in patient
serum samples. Optineurin (OPTN), which has been
reported to be highly expressed in ocular tissues, was
also overexpressed in the serum samples in the context
of chikungunya when compared to that of controls.
Optineurin has also been reported to have anti-viral
signaling role brought about by the negative regulation
of interferon beta [38]. It may be associated with the
EFGNTLEDK
A. Apolipoprotein C-I (APOC1)
























B. Elastase, neutrophil expressed (ELANE)










































































































































































Figure 2 Representative MS/MS spectra of peptides, which were differentially expressed in chikungunya serum samples as compared to
control. (A) MS/MS spectra of 2 peptides from apolipoprotein CI (APOCI), which was found to be in higher abundance in patient sera as compared to
controls, and (B) MS/MS spectra of 2 peptides from elastase, neutrophil expressed (ELANE), which was downregulated in patient sera as compared to
controls. (Insets) Relative intensity of reporter ions (m/z; control serum samples 114, chikungunya serum samples 115) from MS/MS fragmentation.
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Haptoglobin is another acute phase protein that was
overexpressed in patient serum samples [41].
Arthralgia occurs in the majority (~90%) of chikun-




































Figure 3 Functional analysis. (A) molecular function; and (B) biological
ontology. (C) Biological network of differentially regulated proteins.been reported to be the cause of arthritogenic symptoms
in chikungunya [23,25]. Gene expression profiling stud-
ies in mouse models of chikungunya have demonstrated
significant overlap of differentially expressed genes in









































































Figure 4 Overlap of proteins differentially expressed in serum samples of chikungunya patients, with that of differentially expressed
proteins reported in dengue and malaria patients.
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expressed proteins are known to be associated with
arthritis including ANXA1, APOA1, chitinase 3 like-1
(CHI3L1), CLU, COMP, HP, ICOS ligand (ICOSLG) and
lactotransferrin (LTF), among others [42-45].
Apolipoproteins are known to be involved in the lipid
metabolism, particularly in the esterification of choles-
terol. An increase in the serum levels of apolipoproteins
(APOA1, APOA2, APOA4 and APOC1) was observed in
chikungunya patients, which suggests that alterations in
lipid metabolism occur in the context of chikungunya.
Although the exact functions of APOA4 remain un-
known, serum levels of APOA4 are known to be associ-
ated with the higher consumption of dietary lipids [46].
Lipoprotein metabolism has been shown to be modu-
lated in case of viral infections including hepatitis C
virus. Apolipoproteins have been shown to mediate viral
entry into hepatocytes through the formation of lipo-
viro particles and these viral particles are shown to cir-
culate in plasma [47-50].
Rashes are a common symptom of chikungunya infec-
tion. Maculopapular rashes have been reported in ~50%
of the cases. There have been reports of other skin man-
ifestations such as pigmentation and dermatitis in chi-
kungunya patients [39]. In this context, it is interesting
to note that we identified several proteins associated withoncostatin M (OSM) pathway as differentially expressed
in chikungunya, as this pathway has been reported to have
a unique role in hypersensitivity, dermatitis and psoriasis
[51,52]. Although OSM was itself not identified in our
study, proteins including HP, CHI3L1, selenium binding
protein 1 (SELENBP1), S-100 calcium binding proteins
(S100A7, S100A8 and S100A9), and ANXA1, which were
known to be regulated by OSM pathway, were identified
with significant alterations in their expression level from
this investigation [51,53-57].
In recent times, association of chikungunya with neuro-
logical manifestations such as encephalitis and meningo-
encephalitis has been reported, primarily in neonates. It
has also been linked to mortality in chikungunya infected
individuals [58-60]. Post-chikungunya, a few patients have
also presented with Guillain-Barré syndrome (GBS), an
acute inflammatory disorder affecting the peripheral ner-
vous system [61]. Increased levels of APOA4 and HP
observed in our study have been previously reported
from the cerebrospinal fluid of patients with GBS and
Huntington’s disease [62,63].
In isolated reports of neurological manifestations asso-
ciated with chikungunya, documented from Kerala and
Maharashtra in India, significant hyponatremia has been
observed [64,65]. Hyponatremia has also been reported
to be induced in infections such as malaria, dengue, HIV
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mechanisms of the induction of hyponatremia in these
conditions are not well understood, it is associated
with hyperproteinemia and hyperlipidemia [68]. In this
context, we observed overexpression of electrogenic so-
dium bicarbonate cotransporter 1 isoform 2 (SLC4A4) in
serum samples of chikungunya patients, which is known
to regulate the sodium influx along with sodium bicarbon-
ate levels, thereby maintaining the pH of blood [71].
Public availability of proteomic data
We have submitted the proteome data to Human
Proteinpedia [31]. The data can be accessed using the follow-
ing URL: http://www.humanproteinpedia.org/data_display?
exp_id=00708.
We have also submitted the proteome data to the
ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository
[30] with the dataset identifier PXD000234.
Conclusions
This is the first report of an unbiased quantitative prote-
omic profiling of serum from chikungunya patients. It
provides an initial account of changes in serum proteins,
which can initiate new avenues in chikungunya research
to further the understanding of the clinical manifesta-
tions. Our study has identified a number of differentially
expressed proteins, which can be chosen for further val-
idation. In particular, these proteins could be assessed
further for their suitability as candidate biomarkers to
distinguish various vector-borne diseases and for meas-
uring the severity of the disease progression.
Methods
Patient and sample details
Patients with 1–10 days of illness and typical symptoms
like polyarthralgia and fever were worked up for chikun-
gunya infection. Blood samples from patients and ageTable 3 Details of the samples used in this study, with the cli
Sample ID Age Sex Days of illne
Control samples
1 4915 20 Female N/A
2 5308 20 Male N/A
3 4917 40 Female N/A
4 5444 32 Female N/A
Chikungunya infected patient samples (IgM and PCR positive)
1 V-10 4706 63 Male 7
2 V-10 4669 53 Female 7
3 V-10 4663 28 Female 6
4 V-10 4696 45 Female 5
5 V-10 4629 45 Male 7and sex matched controls were obtained after informed
consent and approval of the institutional ethics review
panel at the All India Institute of Medical Sciences, New
Delhi, India (Table 3). Serum was isolated from the
blood sample using standard centrifugation procedures.
The samples were confirmed positive for chikungunya
infection and negative for dengue infection using anti-
CHIKV-IgM capture and anti-Dengue-IgM capture ELISA
kits, respectively (supplied by National Institute of
Virology, Pune, India). Further confirmation of infection
was performed by amplification of chikungunya virus spe-
cific E1 glycoprotein transcripts using RT-PCR [72]. Four
samples that tested negative were used as controls.
RNA extraction and reverse transcriptase PCR (RT-PCR)
RNA from serum samples was isolated using Qiagen
Viral RNA extraction kit and stored at −70°C until use.
cDNA synthesis was carried out using avian myeloblastosis
virus reverse transcriptase and PCR was carried out using
published primers to generate a 294 bp fragment from the
E1 gene of CHIKV [72]. The PCR products were visualized
in 2% agarose gel using ethidium bromide under Gel Doc™
XR + System (Biorad) (Additional file 1: Figure S1). The
identity of the amplicons was further confirmed by
sequencing.
Protein isolation and depletion of abundant proteins
Total protein estimation of these serum samples was
performed using BCA assay (Pierce®. Cat#: 23225) and
normalization of protein amounts were confirmed by
SDS-PAGE. Equivalent amounts of protein from each of
the infected and control serum samples were pooled
separately. Comparable amounts of pooled serum and
control samples were further depleted of the high abun-
dant proteins of serum, using a Multiple Affinity Removal
Spin Cartridge for human serum (Agilent Technologies,
Santa Clara, CA. Cat#: 5188–5230) as per manufacturer’s
instructions.nical presentations at the time of collection
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After depletion, equal amounts of protein from each
sample were processed for further analysis as described
earlier [73]. Briefly, about 70 μg of proteins from each
set was reduced using 2 μL of tris-(2-carboxyethyl)phos-
phine at 60°C for 1 hour, followed by alkylation of cyst-
eine residues using methyl methanethiosulfonate for
10 minutes at room temperature. The samples were then
digested using sequencing grade trypsin (1:20) (Promega,
Madison, WI. Cat#: V5111) at 37°C for 12 hours. The di-
gestion mixture volume was reduced by vacuum drying to
about 40 μL and the peptides in each tube were labeled
with iTRAQ labeling reagents (Applied Biosystems, Cat#:
4352135) following the manufacturer’s protocol. The
infected and control serum samples were labeled with
iTRAQ labels, which will lead to 115 and 114 reporter
ions upon ionization, respectively. After incubating the
samples with the labels for an hour, the reaction was
quenched by addition of 150 μL milliQ water and vac-
uum dried. The labeled peptides from infected and
control serum samples were reconstituted in 5 mM po-
tassium phosphate buffer, 25% acetonitrile (pH 2.7)
(solvent A), pooled and subjected to strong cation ex-
change (SCX) chromatography as described earlier [74].
The labeled peptides were fractionated using polysulfoethyl
A column (PolyLC, Columbia, MD. Cat#: 204SE0502)
(200 Ǻ, 5 μm, 200 × 4.6 mm) on an Agilent 1200 infin-
ity series HPLC system consisting of a binary pump,
external sample injector, UV detector and a fraction
collector. Fractionation was carried out for a period of
50 min using a gradient of increasing salt concentra-
tion of up to 350 mM KCl in solvent A. The eluate was
pooled to obtain 22 fractions, dried in vacuum dryer,
reconstituted in 40 μL of 0.1% trifluoroacetic acid and
desalted using C18 (3 M Empore high-performance
extraction disks) stage-tips.
LC-MS/MS and data analysis
The fractions were analyzed on LTQ-Orbitrap Velos
ETD mass spectrometer (Thermo Scientific, Bremen,
Germany) interfaced with Easy-nLCII (Thermo Scien-
tific, Bremen, Germany). Peptides were initially enriched
on a reversed phase liquid chromatography (RPLC) pre-
column (2 cm, 5 μ – 100 Ǻ), followed by separation on
an analytical column (11 cm, 3 μ – 100 Ǻ) made with
magic AQ C18 material (Michrom Bioresources, Inc,
Auburn, CA) packed in-house. The peptides were sprayed
using nano electro spray emitter tip of 10 μ (New Object-
ive, Woburn, MA). The solvent system used includes 0.1%
aqueous formic acid as solvent A and 100% acetonitrile,
0.1% formic acid as solvent B. The peptides were loaded
on the trap column using 97% solvent A, followed by reso-
lution on the analytical column using a linear gradient of
5-30% solvent B for 70 min at a constant flow rate of0.35 μL/min. The spray voltage and heated capillary
temperature were set to 2.0 kV and 220°C, respectively
and data was acquired in a data dependent manner.
Fifteen most intense precursor ions were selected for
fragmentation from each MS scan. MS and MS/MS
scans were acquired in an Orbitrap mass analyzer at a
resolution of 60,000 at 400 m/z and 15,000, respect-
ively. The peptides were fragmented by higher energy
collision dissociation with normalized collision energy
of 41%. The automatic gain control (AGC) for full FT
MS was set to 1 million ions and for FT MS/MS was
set to 0.1 million ions with maximum accumulation
time of 200 ms and 500 ms, respectively.
The data obtained was searched against the human
RefSeq 52 proteins using Proteome Discoverer, version
1.3.0.339 (Thermo Fischer Scientific, Bremen, Germany)
workflow. The workflow consisted of spectrum selector
and reporter ion quantification nodes in addition to
SEQUEST and Mascot search nodes. Similar parameters
were used in all the searches with trypsin as enzyme
allowing a single missed cleavage. Other parameters in-
clude methylthiol modification of cysteine, iTRAQ labels
at the peptide N-terminus and Lysine residues as static
modifications and oxidation of methionine as variable
modification. A mass tolerance of 20 ppm and 0.1 Da
were used for the precursor ion and fragment ions, re-
spectively with a signal to noise ratio of 1.5 for a precur-
sor mass range of 350–10000 Da. A false discovery rate
(FDR) of 1% was applied to the results. The differentially
expressed proteins obtained from these searches were
analyzed further for functional categorization based on
biological processes and molecular function using annota-
tions in HPRD [32]. The differentially expressed proteins
were further analyzed using the GeneSpring analysis soft-
ware version 12.5 (Agilent Biosystems, Santa Clara, CA),
as described previously [75,76]. We also integrated the
interaction data from NetPath (http://netpath.org) and
HPRD in the analysis using GeneSpring software [77]. Lit-
erature survey was performed to identify serum based
proteome studies in dengue, chikungunya and malaria.
The differentially expressed proteins obtained in this
study were then compared with the differentially expressed
proteins reported in dengue and malaria by other
groups [34-37].Additional file
Additional file 1: Figure S1. Confirmation of chikungunya infection by
RT-PCR. Chikungunya infection was confirmed by the presence of a band
corresponding to 294 bp after PCR amplification.Abbreviations
WHO: World Health Organization; CDC: Centre for Disease Control;
iTRAQ: isobaric tag for Relative and Absolute Quantitation; PSM: Peptide
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http://www.clinicalproteomicsjournal.com/content/10/1/14Spectral Match; PPD: Plasma Proteome Database; HPRD: Human Protein
Reference Database; GBS: Guillain-Barré syndrome; FDR: False Discovery Rate.
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